Quality of Life in Glaucoma: A Review of the Literature

Advances in Therapy

Volumn 33, Issue 6, 2016, Pages 959-981

  Quaranta, Luciano ^a   Riva, Ivano ^a   Gerardi, Chiara ^b   Oddone, Francesco ^c   Floriano, Irene ^b   Konstas, Anastasios G P ^d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c IRCCS FONDAZIONE BIETTI   (Italy)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Glaucoma; Ophthalmology; Quality of life; Quality of life assessment; Visual field loss

Indexed keywords

ANTIGLAUCOMA AGENT;

ANXIETY DISORDER; BINOCULAR VISUAL FIELD LOSS; DAILY LIFE ACTIVITY; DOCTOR PATIENT RELATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MENTAL HEALTH; MONOCULAR VISUAL FIELD LOSS; OCULAR SURFACE DISEASE; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SHORT FORM 36; SOCIAL INTERACTION; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT; DISEASE MANAGEMENT; PATIENT CARE PLANNING; PERIMETRY; PROGNOSIS; PSYCHOLOGY;

DISEASE MANAGEMENT; GLAUCOMA; HUMANS; PATIENT CARE PLANNING; PROGNOSIS; QUALITY OF LIFE; VISUAL FIELD TESTS;

EID: 84965049898     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0333-6     Document Type: Review

References (136)

1. Division of Mental Health and Prevention of Substance Abuse WHO. Measuring quality of life. 1997. http://www.who.int/mental_health/media/68.pdf. Accessed 1 Jan 2016.
2. Felce D, Perry J. Quality of life: its definition and measurement. Res Dev Disabil. 1995;16:51–74.
3. Courtney-Long E, Carroll D, Zhang Q, et al. Prevalence of disability and disability type among adults—United States. MMWR Morb Mortal Wkly Rep. 2013;2015:777–83.
4. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc. 1998;46:58–64.
5. Ivers RQ, Norton R, Cumming RG, Butler M, Campbell AJ. Visual impairment and risk of hip fracture. Am J Epidemiol. 2000;152:633–9.
6. Ribeiro MV, Hasten-Reiter Junior HN, Ribeiro EA, et al. Association between visual impairment and depression in the elderly: a systematic review. Arq Bras Oftalmol. 2015;78:197–201.
7. McGwin G Jr, Xie A, Mays A, et al. Visual field defects and the risk of motor vehicle collisions among patients with glaucoma. Invest Ophthalmol Vis Sci. 2005;46:4437–41.
8. Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49.
9. American Academy of Ophtalmology. Eye disease statistics. 2015: American Academy of Ophthalmology Guidelines.
10. Nirmalan PK, Tielsch JM, Katz J, et al. Relationship between vision impairment and eye disease to vision-specific quality of life and function in rural India: the Aravind Comprehensive Eye Survey. Invest Ophthalmol Vis Sci. 2005;46:2308–12.
11. Broman AT, Munoz B, Rodriguez J, et al. The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci. 2002;43:3393–8.
12. Knudtson MD, Klein BE, Klein R, Cruickshanks KJ, Lee KE. Age-related eye disease, quality of life, and functional activity. Arch Ophthalmol. 2005;123:807–14.
13. Nutheti R, Shamanna BR, Nirmalan PK, et al. Impact of impaired vision and eye disease on quality of life in Andhra Pradesh. Invest Ophthalmol Vis Sci. 2006;47:4742–8.
14. Wu SY, Hennis A, Nemesure B, Leske MC, Barbados Eye Studies Group. Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: the Barbados Eye Studies. Invest Ophthalmol Vis Sci. 2008;49:1333–8.
15. Bullinger M. Ensuring international equivalence of quality of life measures: problems and approaches to solution. In: Orley J, Kuyken W, editors. Quality of life assessment: international perspectives. Heidelberg: Springer; 1994. p. 33–40.
16. Power M, Harper A, Bullinger M. The World Health Organization WHOQOL-100: tests of the universality of quality of Life in 15 different cultural groups worldwide. Health Psychol. 1999;18:495–505.
17. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
18. Kurtin PS, Davies AR, Meyer KB, DeGiacomo JM, Kantz ME. Patient-based health status measures in outpatient dialysis. Early experiences in developing an outcomes assessment program. Med Care. 1992;30:MS136–49.
19. Nerenz DR, Repasky DP, Whitehouse FW, Kahkonen DM. Ongoing assessment of health status in patients with diabetes mellitus. Med Care. 1992;30:MS112–24.
20. Kantz ME, Harris WJ, Levitsky K, Ware JE Jr, Davies AR. Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. Med Care. 1992;30:MS240–52.
21. Wachtel T, Piette J, Mor V, et al. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med. 1992;116:129–37.
22. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786–98.
23. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
24. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.
25. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4:222–31.
26. Gordon MO, Kass MA. The ocular hypertension treatment study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573–83.
27. Wilson MR, Coleman AL, Yu F, et al. Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology. 1998;105:2112–6.
28. Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmol Scand. 2001;79:121–4.
29. Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmol Scand. 2001;79:116–20.
30. Parrish RK 2nd, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115:1447–55.
31. Cypel MC, Kasahara N, Atique D, et al. Quality of life in patients with glaucoma who live in a developing country. Int Ophthalmol. 2004;25:267–72.
32. Mills T, Law SK, Walt J, Buchholz P, Hansen J. Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs Aging. 2009;26:933–50.
33. Kobelt G, Jonsson B, Bergstrom A, et al. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand. 2006;84:363–71.
34. Aspinall PA, Johnson ZK, Azuara-Blanco A, et al. Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol Vis Sci. 2008;49:1907–15.
35. Vandenbroeck S, De Geest S, Zeyen T, Stalmans I, Dobbels F. Patient-reported outcomes (PRO’s) in glaucoma: a systematic review. Eye (Lond). 2011;25:555–77.
36. Varma R, Richman EA, Ferris FL 3rd, Bressler NM. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA clinical trial endpoints symposium. Invest Ophthalmol Vis Sci. 2010;51:6095–103.
37. Leidy NK. Functional status and the forward progress of merry-go-rounds: toward a coherent analytical framework. Nurs Res. 1994;43:196–202.
38. Turano KA, Geruschat DR, Stahl JW, Massof RW. Perceived visual ability for independent mobility in persons with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1999;40:865–77.
39. Turano KA, Massof RW, Quigley HA. A self-assessment instrument designed for measuring independent mobility in RP patients: generalizability to glaucoma patients. Invest Ophthalmol Vis Sci. 2002;43:2874–81.
40. Walt JG, Rendas-Baum R, Kosinski M, Patel V. Psychometric evaluation of the glaucoma symptom identifier. J Glaucoma. 2011;20:148–59.
41. Mangione CM, Berry S, Spritzer K, et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol. 1998;116:227–33.
42. Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the national eye institute visual function questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116:1496–504.
43. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119:1050–8.
44. Hyman LG, Komaroff E, Heijl A, et al. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005;112:1505–13.
45. Leske MC, Heijl A, Hyman L, Bengtsson B. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106:2144–53.
46. Gedde SJ, Schiffman JC, Feuer WJ, et al. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005;140:275–87.
47. Bechetoille A, Arnould B, Bron A, et al. Measurement of health-related quality of life with glaucoma: validation of the Glau-QoL 36-item questionnaire. Acta Ophthalmol. 2008;86:71–80.
48. Janz NK, Wren PA, Lichter PR, et al. Quality of life in newly diagnosed glaucoma patients: the collaborative initial glaucoma treatment study. Ophthalmology. 2001;108:887–97 (discussion 898).
49. Mills RP, Janz NK, Wren PA, Guire KE. Correlation of visual field with quality-of-life measures at diagnosis in the collaborative initial glaucoma treatment study (CIGTS). J Glaucoma. 2001;10:192–8.
50. Burr JM, Kilonzo M, Vale L, Ryan M. Developing a preference-based Glaucoma Utility Index using a discrete choice experiment. Optom Vis Sci. 2007;84:797–808.
51. Atkinson MJ, Stewart WC, Fain JM, et al. A new measure of patient satisfaction with ocular hypotensive medications: the treatment satisfaction survey for intraocular pressure (TSS-IOP). Health Qual Life Outcomes. 2003;1:67.
52. Day DG, Sharpe ED, Atkinson MJ, Stewart JA, Stewart WC. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye (Lond). 2006;20:583–90.
53. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology. 1997;104:334–42.
54. European Glaucoma Society. Terminology and guidelines for glaucoma. IV ed. Savona: Editrice DOGMA; 2014.
55. National Institute for Health and Care Excellence. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension [CG85]. London: National Collaborating Centre for Acute Care; 2009.
56. Thygesen J, Aagren M, Arnavielle S, et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin. 2008;24:1763–70.
57. Gupta V, Srinivasan G, Mei SS, et al. Utility values among glaucoma patients: an impact on the quality of life. Br J Ophthalmol. 2005;89:1241–4.
58. Peters D, Heijl A, Brenner L, Bengtsson B. Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up. Acta Ophthalmol. 2015;93:745–52.
59. Musch DC, Lichter PR, Guire KE, Standardi CL. The collaborative initial glaucoma treatment study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653–62.
60. Wolfram C, Lorenz K, Breitscheidel L, Verboven Y, Pfeiffer N. Health- and vision-related quality of life in patients with ocular hypertension or primary open-angle glaucoma. Ophthalmologica. 2013;229:227–34.
61. Viswanathan AC, McNaught AI, Poinoosawmy D, et al. Severity and stability of glaucoma: patient perception compared with objective measurement. Arch Ophthalmol. 1999;117:450–4.
62. Iester M, Zingirian M. Quality of life in patients with early, moderate and advanced glaucoma. Eye (Lond). 2002;16:44–9.
63. Globe DR, Schoua-Glusberg A, Paz S, et al. Using focus groups to develop a culturally sensitive methodology for epidemiological surveys in a Latino population: findings from the Los Angeles Latino Eye Study (LALES). Ethn Dis. 2002;12:259–66.
64. McKean-Cowdin R, Wang Y, Wu J, et al. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(941–948):e941.
65. Richman J, Lorenzana LL, Lankaranian D, et al. Relationships in glaucoma patients between standard vision tests, quality of life, and ability to perform daily activities. Ophthalmic Epidemiol. 2010;17:144–51.
66. Friedman DS, Freeman E, Munoz B, Jampel HD, West SK. Glaucoma and mobility performance: the Salisbury eye evaluation project. Ophthalmology. 2007;114:2232–7.
67. Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48:1149–55.
68. Haymes SA, LeBlanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Glaucoma and on-road driving performance. Invest Ophthalmol Vis Sci. 2008;49:3035–41.
69. Ramulu P. Glaucoma and disability: which tasks are affected, and at what stage of disease? Curr Opin Ophthalmol. 2009;20:92–8.
70. van Gestel A, Webers CA, Beckers HJ, et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond). 2010;24:1759–69.
71. Sawada H, Yoshino T, Fukuchi T, Abe H. Assessment of the vision-specific quality of life using clustered visual field in glaucoma patients. J Glaucoma. 2014;23:81–7.
72. Cheng HC, Guo CY, Chen MJ, et al. Patient-reported vision-related quality of life differences between superior and inferior hemifield visual field defects in primary open-angle glaucoma. JAMA Ophthalmol. 2015;133:269–75.
73. Asaoka R, Crabb DP, Yamashita T, et al. Patients have two eyes!: binocular versus better eye visual field indices. Invest Ophthalmol Vis Sci. 2011;52:7007–11.
74. Turano KA, Broman AT, Bandeen-Roche K, et al. Association of visual field loss and mobility performance in older adults: Salisbury eye evaluation study. Optom Vis Sci. 2004;81:298–307.
75. Black AA, Wood JM, Lovie-Kitchin JE. Inferior field loss increases rate of falls in older adults with glaucoma. Optom Vis Sci. 2011;88:1275–82.
76. Medeiros FA, Gracitelli CP, Boer ER, et al. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology. 2015;122:293–301.
77. Agorastos A, Skevas C, Matthaei M, et al. Depression, anxiety, and disturbed sleep in glaucoma. J Neuropsychiatry Clin Neurosci. 2013;25:205–13.
78. Hollo G, Kothy P, Geczy A, Vargha P. Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma. J Glaucoma. 2009;18:288–92.
79. Jampel HD, Frick KD, Janz NK, et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol. 2007;144:238–44.
80. Mabuchi F, Yoshimura K, Kashiwagi K, et al. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. J Glaucoma. 2008;17:552–7.
81. Mabuchi F, Yoshimura K, Kashiwagi K, et al. Risk factors for anxiety and depression in patients with glaucoma. Br J Ophthalmol. 2012;96:821–5.
82. Popescu ML, Boisjoly H, Schmaltz H, et al. Explaining the relationship between three eye diseases and depressive symptoms in older adults. Invest Ophthalmol Vis Sci. 2012;53:2308–13.
83. Skalicky S, Goldberg I. Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. J Glaucoma. 2008;17:546–51.
84. Wang SY, Singh K, Lin SC. Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample. Am J Ophthalmol. 2012;154(436–444):e432.
85. Wilson MR, Coleman AL, Yu F, et al. Depression in patients with glaucoma as measured by self-report surveys. Ophthalmology. 2002;109:1018–22.
86. Yochim BP, Mueller AE, Kane KD, Kahook MY. Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma. J Glaucoma. 2012;21:250–4.
87. Janz NK, Wren PA, Guire KE, et al. Fear of blindness in the collaborative initial glaucoma treatment study: patterns and correlates over time. Ophthalmology. 2007;114:2213–20.
88. Ramulu PY, West SK, Munoz B, Jampel HD, Friedman DS. Driving cessation and driving limitation in glaucoma: the Salisbury Eye Evaluation Project. Ophthalmology. 2009;116:1846–53.
89. Campbell MK, Bush TL, Hale WE. Medical conditions associated with driving cessation in community-dwelling, ambulatory elders. J Gerontol. 1993;48:S230–4.
90. Freeman EE, Munoz B, Rubin G, West SK. Visual field loss increases the risk of falls in older adults: the Salisbury eye evaluation. Invest Ophthalmol Vis Sci. 2007;48:4445–50.
91. Murphy SL, Dubin JA, Gill TM. The development of fear of falling among community-living older women: predisposing factors and subsequent fall events. J Gerontol A Biol Sci Med Sci. 2003;58:M943–7.
92. Thomas SA, Friedmann E, Kao CW, et al. Quality of life and psychological status of patients with implantable cardioverter defibrillators. Am J Crit Care. 2006;15:389–98.
93. Nelson CJ, Weinberger MI, Balk E, et al. The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist. 2009;14:891–9.
94. Hugues FC, Le Jeunne C. Systemic and local tolerability of ophthalmic drug formulations. An update. Drug Saf. 1993;8:365–80.
95. Guldvog B. Can patient satisfaction improve health among patients with angina pectoris? Int J Qual Health Care. 1999;11:233–40.
96. Donabedian A. The quality of care. How can it be assessed? JAMA. 1988;260:1743–8.
97. Marquis MS, Davies AR, Ware JE Jr. Patient satisfaction and change in medical care provider: a longitudinal study. Med Care. 1983;21:821–9.
98. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–8.
99. Jampel HD, Schwartz GF, Robin AL, et al. Patient preferences for eye drop characteristics: a willingness-to-pay analysis. Arch Ophthalmol. 2003;121:540–6.
100. Balkrishnan R, Bond JB, Byerly WG, Camacho FT, Anderson RT. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organization. Am J Geriatr Pharmacother. 2003;1:75–81.
101. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57–68.
102. Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–6.
103. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.
104. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–8.
105. Lee BL, Wilson MR. Health-related quality of life in patients with cataract and glaucoma. J Glaucoma. 2000;9:87–94.
106. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–5.
107. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–8.
108. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–34.
109. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–26.
110. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–6.
111. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1–9):e2.
112. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21.
113. Rossi GC, Pasinetti GM, Scudeller L, Bianchi PE. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther. 2013;29:390–4.
114. Rossi GC, Pasinetti GM, Scudeller L, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23:296–302.
115. Baudouin C, Renard JP, Nordmann JP, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013;23:47–54.
116. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–36.
117. Januleviciene I, Derkac I, Grybauskiene L, et al. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103–9.
118. Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97:196–200.
119. Cucherat M, Stalmans I, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014;23:e69–75.
120. Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60–4.
121. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci. 2003;44:4753–61.
122. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23:762–70.
123. Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954–65.
124. Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2012;9:CD004399.
125. Guedes RA, Guedes VM, Freitas SM, Chaoubah A. Quality of life of medically versus surgically treated glaucoma patients. J Glaucoma. 2013;22:369–73.
126. Nelson P, Aspinall P, Papasouliotis O, Worton B, O’Brien C. Quality of life in glaucoma and its relationship with visual function. J Glaucoma. 2003;12:139–50.
127. Ramulu PY, Maul E, Hochberg C, et al. Real-world assessment of physical activity in glaucoma using an accelerometer. Ophthalmology. 2012;119:1159–66.
128. Freeman EE, Munoz B, West SK, Jampel HD, Friedman DS. Glaucoma and quality of life: the Salisbury eye evaluation. Ophthalmology. 2008;115:233–8.
129. Friedman SM, Munoz B, Rubin GS, et al. Characteristics of discrepancies between self-reported visual function and measured reading speed. Salisbury Eye Evaluation Project Team. Invest Ophthalmol Vis Sci. 1999;40:858–64.
130. Foley DJ, Heimovitz HK, Guralnik JM, Brock DB. Driving life expectancy of persons aged 70 years and older in the United States. Am J Public Health. 2002;92:1284–9.
131. McKean-Cowdin R, Varma R, Wu J, et al. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143:1013–23.
132. van Landingham SW, Hochberg C, Massof RW, et al. Driving patterns in older adults with glaucoma. BMC Ophthalmol. 2013;13:4.
133. Gilhotra JS, Mitchell P, Ivers R, Cumming RG. Impaired vision and other factors associated with driving cessation in the elderly: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2001;29:104–7.
134. Freeman EE, Munoz B, Turano KA, West SK. Measures of visual function and their association with driving modification in older adults. Invest Ophthalmol Vis Sci. 2006;47:514–20.
135. Blane A. Through the looking glass: a review of the literature investigating the impact of glaucoma on crash risk, driving performance, and driver self-regulation in older drivers. J Glaucoma. 2014;25:113–21.
136. Lee PP. Outcomes and endpoints in glaucoma. J Glaucoma. 1996;5:295–7.